{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T06:14:41Z","timestamp":1781676881121,"version":"3.54.5"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI145453)"],"award-info":[{"award-number":["R01AI145453)"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>QUANTI-TAF aimed to establish tenofovir-diphosphate (TFV-DP)\/emtricitabine-triphosphate (FTC-TP) adherence benchmarks in dried blood spots (DBS) for persons with human immunodeficiency virus (PWH) receiving tenofovir alafenamide\/emtricitabine (TAF\/FTC)\u2013based antiretroviral therapy (ART).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>For 16 weeks, PWH received TAF\/FTC-based ART co-encapsulated with an ingestible sensor to directly measure cumulative (enrollment to final visit) and 10-day adherence. At monthly visits, intraerythrocytic concentrations of TFV-DP and FTC-TP in DBS were quantified and summarized at steady-state (week 12 or 16) as median (interquartile range). Linear mixed-effects models evaluated factors associated with TFV-DP\/FTC-TP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-four participants (11% female, 4% transgender) predominantly receiving bictegravir\/TAF\/FTC (73%) were enrolled. Ninety-two percent completed week 12 or 16 (94% unboosted ART). TFV-DP for &amp;lt;85% (7\/72), 85%\u2013&amp;lt;95% (9\/72), and \u226595% (56\/72) cumulative adherence was 2696 (2039\u20134108), 3117 (2332\u20133339), and 3344 (2605\u20134293) fmol\/punches. Adjusting for cumulative adherence, TFV-DP was higher with boosted ART, lower body mass index, and in non-Black participants. FTC-TP for &amp;lt;85% (14\/77), 85%\u2013&amp;lt;95% (6\/77), and \u226595% (57\/77) 10-day adherence was 3.52 (2.64\u20134.48), 4.58 (4.39\u20135.06), and 4.96 (4.21\u20136.26) pmol\/punches. All participants with \u226585% cumulative and 10-day adherence had TFV-DP \u22651800 fmol\/punches and FTC-TP \u22652.5 pmol\/punches, respectively. Low-level viremia (HIV-1 RNA 20\u2013199\u2005copies\/mL) occurred at 18% of visits in 39% of participants with similar TFV-DP (3177 [2494\u20134149] fmol\/punches) compared with suppressed visits (3279 [2580\u20134407] fmol\/punches).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>TFV-DP \u22651800\u2005fmol\/punches and FTC-TP \u22652.5\u2005pmol\/punches represent DBS benchmarks for \u226585% adherence to unboosted TAF\/FTC-based ART. Among PWH with high adherence, low-level viremia was common.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04065347.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae212","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T18:17:43Z","timestamp":1713464263000},"page":"1233-1241","source":"Crossref","is-referenced-by-count":10,"title":["Tenofovir-Diphosphate and Emtricitabine-Triphosphate Adherence Benchmarks in Dried Blood Spots for Persons With HIV Receiving Tenofovir Alafenamide and Emtricitabine\u2013Based Antiretroviral Therapy (QUANTI-TAF)"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-7020","authenticated-orcid":false,"given":"Ryan P","family":"Coyle","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Morrow","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C","family":"Mann","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Mainella","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel L","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Schwab","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corwin","family":"Coppinger","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Ellison","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Hua","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhi","family":"Al Zuabi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela E","family":"Alpert","sequence":"additional","affiliation":[{"name":"etectRx , Gainesville, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony C","family":"Carnes","sequence":"additional","affiliation":[{"name":"etectRx , Gainesville, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"D Eric","family":"Buffkin","sequence":"additional","affiliation":[{"name":"etectRx , Gainesville, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0955-4117","authenticated-orcid":false,"given":"Peter R","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, Massachusetts ,","place":["USA"]},{"name":"Koch Institute for Integrated Cancer Research, Massachusetts Institute of Technology , Cambridge, Massachusetts ,","place":["USA"]},{"name":"The Fenway Institute , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lane R","family":"Bushman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J","family":"Kiser","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]},{"name":"Medical Affairs, Merck & Co, Inc , Rahway, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"MaWhinney","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina M","family":"Brooks","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-8494","authenticated-orcid":false,"given":"Peter L","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R","family":"Castillo-Mancilla","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]},{"name":"Clinical Development, ViiV Healthcare , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2024112123533073200_ciae212-B1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","article-title":"Antiretroviral adherence level necessary for HIV viral suppression using real-world data","volume":"82","author":"Byrd","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024112123533073200_ciae212-B2","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3018(21)00300-3","article-title":"A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial","volume":"9","author":"Landman","year":"2022","journal-title":"Lancet HIV"},{"key":"2024112123533073200_ciae212-B3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/jpm13040583","article-title":"Intermittent bictegravir\/emtricitabine\/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV","volume":"13","author":"Sellem","year":"2023","journal-title":"J Pers Med"},{"key":"2024112123533073200_ciae212-B4","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/cid\/ciw650","article-title":"Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression","volume":"63","author":"Castillo-Mancilla","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024112123533073200_ciae212-B5","doi-asserted-by":"crossref","first-page":"e0155100","DOI":"10.1371\/journal.pone.0155100","article-title":"Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PLoS One"},{"key":"2024112123533073200_ciae212-B6","doi-asserted-by":"crossref","first-page":"ofad230","DOI":"10.1093\/ofid\/ofad230","article-title":"Beyond undetectable: modeling the clinical benefit of improved antiretroviral adherence in persons with human immunodeficiency virus with virologic suppression","volume":"10","author":"Castillo-Mancilla","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024112123533073200_ciae212-B7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAD.0000000000000123","article-title":"Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia","volume":"28","author":"Li","year":"2014","journal-title":"AIDS"},{"key":"2024112123533073200_ciae212-B8","doi-asserted-by":"crossref","first-page":"ofab463","DOI":"10.1093\/ofid\/ofab463","article-title":"Low-level viremia is associated with cumulative adherence to antiretroviral therapy in persons with HIV","volume":"8","author":"Castillo-Mancilla","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024112123533073200_ciae212-B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024112123533073200_ciae212-B10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/jac\/dkad056","article-title":"Low-level viral loads and virological failure in the integrase strand transfer era","volume":"78","author":"Cuzin","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024112123533073200_ciae212-B11","article-title":"Beyond HIV viral load: application of pharmacologic measures to identify ART adherence mismatch","volume":"8","author":"Kristofich","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"2024112123533073200_ciae212-B12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/cpt.1201","article-title":"Pharmacologic-based methods of adherence assessment in HIV prevention","volume":"104","author":"Brooks","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2024112123533073200_ciae212-B13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11904-020-00502-5","article-title":"Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions","volume":"17","author":"Spinelli","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024112123533073200_ciae212-B14","doi-asserted-by":"crossref","first-page":"e01710-17","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy","volume":"62","author":"Anderson","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112123533073200_ciae212-B15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","article-title":"Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS study","volume":"84","author":"Yager","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024112123533073200_ciae212-B16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/cpt.2845","article-title":"A novel algorithm to improve PrEP adherence monitoring using dried blood spots","volume":"113","author":"Devanathan","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2024112123533073200_ciae212-B17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2024112123533073200_ciae212-B18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2024112123533073200_ciae212-B19","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/cid\/ciad021","article-title":"Updating the adherence-response for oral emtricitabine\/tenofovir disoproxil fumarate for human immunodeficiency virus pre-exposure prophylaxis among cisgender women","volume":"76","author":"Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024112123533073200_ciae212-B20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/cid\/ciy708","article-title":"Tenofovir diphosphate in dried blood spots is strongly associated with viral suppression in individuals with HIV infection","volume":"68","author":"Castillo-Mancilla","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024112123533073200_ciae212-B21","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dky559","article-title":"Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy","volume":"74","author":"Frasca","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024112123533073200_ciae212-B22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jiz144","article-title":"Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV","volume":"220","author":"Morrow","year":"2019","journal-title":"J Infect Dis"},{"key":"2024112123533073200_ciae212-B23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/QAD.0000000000002981","article-title":"Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence","volume":"35","author":"Morrow","year":"2021","journal-title":"AIDS"},{"key":"2024112123533073200_ciae212-B24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"2024112123533073200_ciae212-B25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024112123533073200_ciae212-B26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","article-title":"Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals","volume":"78","author":"Begley","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024112123533073200_ciae212-B27","first-page":"12","article-title":"Performance, reliability, usability, and safety of the ID-Cap system for ingestion event monitoring in healthy volunteers: a pilot study","volume":"13","author":"Flores","year":"2016","journal-title":"Innov Clin Neurosci"},{"key":"2024112123533073200_ciae212-B28","doi-asserted-by":"crossref","first-page":"e30786","DOI":"10.2196\/30786","article-title":"A novel digital pill system for medication adherence measurement and reporting: usability validation study","volume":"8","author":"Baumgartner","year":"2021","journal-title":"JMIR Hum Factors"},{"key":"2024112123533073200_ciae212-B29","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/QAI.0000000000002854","article-title":"DigiPrEP: a pilot trial to evaluate the feasibility, acceptability, and accuracy of a digital pill system to measure PrEP adherence in men who have sex with men who use substances","volume":"89","author":"Chai","year":"2022","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024112123533073200_ciae212-B30","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/aid.2018.0073","article-title":"Short communication: bioequivalence of tenofovir component of tenofovir\/rilpivirine\/emtricitabine in digital pills","volume":"35","author":"Chai","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024112123533073200_ciae212-B31","doi-asserted-by":"crossref","first-page":"107051","DOI":"10.1016\/j.cct.2022.107051","article-title":"Improving the accuracy of adherence data collected using medication monitoring technology in clinical research","volume":"125","author":"Morrow","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"2024112123533073200_ciae212-B32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpba.2016.01.038","article-title":"Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots","volume":"122","author":"Zheng","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"2024112123533073200_ciae212-B33","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/jac\/dkaa070","article-title":"Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV","volume":"75","author":"Coyle","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024112123533073200_ciae212-B34","doi-asserted-by":"crossref","DOI":"10.1177\/2325958219888457","article-title":"Moderately high tenofovir diphosphate in dried blood spots indicates drug resistance in viremic persons living with HIV","volume":"18","author":"Yager","year":"2019","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2024112123533073200_ciae212-B35","doi-asserted-by":"crossref","first-page":"e25849","DOI":"10.1002\/jia2.25849","article-title":"Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study","volume":"24","author":"Castillo-Mancilla","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2024112123533073200_ciae212-B36","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1038\/s41591-023-02611-1","article-title":"Viral and host mediators of non-suppressible HIV-1 viremia","volume":"29","author":"Mohammadi","year":"2023","journal-title":"Nat Med"},{"key":"2024112123533073200_ciae212-B37","doi-asserted-by":"crossref","first-page":"2021-8-13","DOI":"10.7573\/dic.2021-8-13","article-title":"HIV: how to manage low-level viraemia in people living with HIV","volume":"11","author":"Hanners","year":"2022","journal-title":"Drugs Context"},{"key":"2024112123533073200_ciae212-B38","article-title":"Ingestible electronic sensors to measure instantaneous medication adherence: a narrative review","volume":"8","author":"Chai","year":"2022","journal-title":"Digit Health"},{"key":"2024112123533073200_ciae212-B39","doi-asserted-by":"crossref","first-page":"104330","DOI":"10.1016\/j.ebiom.2022.104330","article-title":"Ingestible sensor system for measuring, monitoring and enhancing adherence to antiretroviral therapy: an open-label, usual care-controlled, randomised trial","volume":"86","author":"Liu","year":"2022","journal-title":"EBioMedicine"},{"key":"2024112123533073200_ciae212-B40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciac280","article-title":"Supporting the art: medication adherence patterns in persons prescribed ingestible sensor-enabled oral pre-exposure prophylaxis to prevent human immunodeficiency virus infection","volume":"76","author":"Browne","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae212\/57504653\/ciae212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/5\/1233\/60779420\/ciae212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/5\/1233\/60779420\/ciae212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T23:54:41Z","timestamp":1732233281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/5\/1233\/7651019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,4,18]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae212","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,15]]},"published":{"date-parts":[[2024,4,18]]}}}